Amalgamated Bank Raises Position in Axon Enterprise, Inc (NASDAQ:AXON)

Amalgamated Bank boosted its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 3.7% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,429 shares of the biotechnology company's stock after acquiring an additional 556 shares during the period. Amalgamated Bank's holdings in Axon Enterprise were worth $8,115,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fourth Dimension Wealth LLC acquired a new position in Axon Enterprise during the 4th quarter worth approximately $30,000. Bartlett & CO. Wealth Management LLC boosted its holdings in shares of Axon Enterprise by 132.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock valued at $31,000 after buying an additional 33 shares in the last quarter. Alpine Bank Wealth Management acquired a new position in shares of Axon Enterprise in the 1st quarter valued at $40,000. Elequin Capital LP acquired a new position in shares of Axon Enterprise in the 4th quarter valued at $46,000. Finally, CoreFirst Bank & Trust acquired a new position in shares of Axon Enterprise in the 4th quarter valued at $59,000. Institutional investors and hedge funds own 79.08% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Craig Hallum cut shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a report on Monday, March 10th. Barclays upped their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a report on Friday, May 9th. The Goldman Sachs Group upped their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a report on Wednesday, May 14th. Needham & Company LLC upped their target price on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Finally, Bank of America upped their target price on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a report on Wednesday, June 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $699.55.

Axon Enterprise Stock Performance

NASDAQ:AXON traded up $20.93 during trading hours on Friday, reaching $795.48. 268,670 shares of the company's stock were exchanged, compared to its average volume of 540,118. The firm has a market capitalization of $61.93 billion, a price-to-earnings ratio of 192.14, a P/E/G ratio of 91.57 and a beta of 1.29. The company has a 50-day moving average of $736.97 and a 200 day moving average of $635.97. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68. Axon Enterprise, Inc has a 1-year low of $279.02 and a 1-year high of $830.21.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.34 by $0.07. The company had revenue of $603.63 million during the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The business's revenue was up 31.3% on a year-over-year basis. During the same quarter last year, the business earned $1.15 EPS. Research analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Insiders Place Their Bets

In other news, Director Michael Garnreiter sold 5,913 shares of Axon Enterprise stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $760.00, for a total value of $4,493,880.00. Following the sale, the director owned 17,740 shares of the company's stock, valued at $13,482,400. The trade was a 25.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 1,300 shares of Axon Enterprise stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $738.84, for a total transaction of $960,492.00. Following the completion of the sale, the director directly owned 4,829 shares in the company, valued at approximately $3,567,858.36. The trade was a 21.21% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 44,642 shares of company stock valued at $30,500,428. Corporate insiders own 4.40% of the company's stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.